XML 43 R24.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Schedule I (Notes) | 12 Months Ended
--- | ---
Dec. 31, 2024
Condensed Statement of Income Captions [Line Items] |
Condensed Financial Information of Parent Company Only Disclosure [Text Block] | Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Balance Sheets
(in millions, except per share data) |  | December 31, 2024 |  | December 31, 2023
Assets |  |  |  |
Current assets: |  |  |  |
Cash and cash equivalents |  | $ | 234 |  |  | $ | 776 |
Other current assets |  | 411 |  |  | 570 |
Total current assets |  | 645 |  |  | 1,346 |
Equity in net assets of subsidiaries |  | 179,209 |  |  | 153,692 |
Long-term notes receivable from subsidiaries |  | 6,062 |  |  | 5,693 |
Other assets |  | 920 |  |  | 831 |
Total assets |  | $ | 186,836 |  |  | $ | 161,562 |
Liabilities and shareholders’ equity |  |  |  |
Current liabilities: |  |  |  |
Accounts payable and accrued liabilities |  | $ | 1,501 |  |  | $ | 1,116 |
Short-term notes payable to subsidiaries |  | 2,016 |  |  | 9,887 |
Short-term borrowings and current maturities of long-term debt |  | 4,348 |  |  | 4,086 |
Total current liabilities |  | 7,865 |  |  | 15,089 |
Long-term debt, less current maturities |  | 71,831 |  |  | 57,387 |
Long-term notes payable to subsidiaries |  | 14,405 |  |  | — |
Other liabilities |  | 77 |  |  | 330 |
Total liabilities |  | 94,178 |  |  | 72,806 |
Commitments and contingencies (Note 4) |  |  |  |
Shareholders’ equity: |  |  |  |
Preferred stock, $0.001 par value -10 shares authorized; no shares issued or outstanding |  | — |  |  | — |
Common stock, $0.01 par value - 3,000 shares authorized; 915 and 924 issued and outstanding |  | 9 |  |  | 9 |
Retained earnings |  | 96,036 |  |  | 95,774 |
Accumulated other comprehensive loss |  | (3,387) |  |  | (7,027) |
Total UnitedHealth Group shareholders’ equity |  | 92,658 |  |  | 88,756 |
Total liabilities and shareholders’ equity |  | $ | 186,836 |  |  | $ | 161,562 |
See Notes to the Condensed Financial Statements of Registrant Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Statements of Comprehensive Income
|  | For the Years Ended December 31,
(in millions) |  | 2024 |  | 2023 |  | 2022
Revenues: |  |  |  |  |  |
Investment and other income |  | $ | 368 |  |  | $ | 312 |  |  | $ | 255 |
Total revenues |  | 368 |  |  | 312 |  |  | 255 |
Operating costs: |  |  |  |  |  |
Operating costs |  | 108 |  |  | 35 |  |  | 121 |
Interest expense |  | 4,544 |  |  | 3,469 |  |  | 2,110 |
Total operating costs |  | 4,652 |  |  | 3,504 |  |  | 2,231 |
Loss before income taxes |  | (4,284) |  |  | (3,192) |  |  | (1,976) |
Benefit for income taxes |  | 1,032 |  |  | 654 |  |  | 429 |
Loss of parent company |  | (3,252) |  |  | (2,538) |  |  | (1,547) |
Equity in undistributed income of subsidiaries |  | 17,657 |  |  | 24,919 |  |  | 21,667 |
Net earnings |  | 14,405 |  |  | 22,381 |  |  | 20,120 |
Other comprehensive income (loss) |  | 3,640 |  |  | 1,366 |  |  | (3,009) |
Comprehensive income |  | $ | 18,045 |  |  | $ | 23,747 |  |  | $ | 17,111 |
See Notes to the Condensed Financial Statements of Registrant Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Statements of Cash Flows
|  | For the Years Ended December 31,
(in millions) |  | 2024 |  | 2023 |  | 2022
Operating activities |  |  |  |  |  |
Cash flows from operating activities |  | $ | 4,852 |  |  | $ | 17,443 |  |  | $ | 14,754 |
Investing activities |  |  |  |  |  |
Issuances of notes to subsidiaries |  | (349) |  |  | (41) |  |  | (567) |
Repayments of notes to subsidiaries |  | 225 |  |  | 817 |  |  | 281 |
Cash paid for acquisitions and other transactions |  | (13,750) |  |  | (8,144) |  |  | (20,728) |
Return of capital to parent company |  | 21 |  |  | 639 |  |  | 1,424 |
Capital contributions to subsidiaries |  | — |  |  | (2,472) |  |  | (570) |
Cash received from dispositions, net |  | 2,444 |  |  | 624 |  |  | 2,787 |
Other, net |  | 30 |  |  | 286 |  |  | — |
Cash flows used for investing activities |  | (11,379) |  |  | (8,291) |  |  | (17,373) |
Financing activities |  |  |  |  |  |
Common stock repurchases |  | (9,000) |  |  | (8,000) |  |  | (7,000) |
Proceeds from common stock issuances |  | 1,846 |  |  | 1,353 |  |  | 1,253 |
Cash dividends paid |  | (7,533) |  |  | (6,761) |  |  | (5,991) |
(Repayments of) proceeds from short-term borrowings, net |  | (151) |  |  | 11 |  |  | 732 |
Proceeds from issuance of long-term debt |  | 17,811 |  |  | 6,394 |  |  | 14,819 |
Repayments of long-term debt |  | (3,000) |  |  | (2,125) |  |  | (3,015) |
(Repayments of) proceeds from short-term notes from subsidiaries, net |  | (7,966) |  |  | 1,188 |  |  | 594 |
Proceeds from long-term notes from subsidiaries |  | 14,396 |  |  | — |  |  | — |
Repayments of long-term notes from subsidiaries |  | (28) |  |  | — |  |  | — |
Other, net |  | (390) |  |  | (702) |  |  | (674) |
Cash flows from (used for) financing activities |  | 5,985 |  |  | (8,642) |  |  | 718 |
(Decrease) increase in cash and cash equivalents |  | (542) |  |  | 510 |  |  | (1,901) |
Cash and cash equivalents, beginning of period |  | 776 |  |  | 266 |  |  | 2,167 |
Cash and cash equivalents, end of period |  | $ | 234 |  |  | $ | 776 |  |  | $ | 266 |
Supplemental cash flow disclosures |  |  |  |  |  |
Cash paid for interest |  | $ | 4,241 |  |  | $ | 3,257 |  |  | $ | 1,969 |
Cash paid for income taxes |  | 2,450 |  |  | 4,426 |  |  | 4,298 |
See Notes to the Condensed Financial Statements of Registrant Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Notes to Condensed Financial Statements 1. Basis of Presentation UnitedHealth Group’s parent company financial information has been derived from its consolidated financial statements and should be read in conjunction with the consolidated financial statements included in this Form 10-K. The accounting policies for the registrant are the same as those described in Note 2 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.” 2. Subsidiary Transactions Investment in Subsidiaries. UnitedHealth Group’s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries. Dividends and Capital Distributions. Cash dividends received from subsidiaries and included in Cash Flows from Operating Activities in the Condensed Statements of Cash Flows were $19.3 billion, $18.5 billion and $15.6 billion in 2024, 2023 and 2022, respectively. Additionally, $21 million, $639 million and $1.4 billion in cash were received as a return of capital to the parent company during 2024, 2023 and 2022, respectively. 3. Short-Term Borrowings and Long-Term Debt Discussion of short-term borrowings and long-term debt can be found in Note 8 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.” Long-term debt obligations of the parent company do not include other financing obligations at subsidiaries which totaled $0.7 billion and $1.1 billion at December 31, 2024 and 2023. Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows:
(in millions) |  |
2025 |  | $ | 4,350 |
2026 |  | 3,650 |
2027 |  | 3,425 |
2028 |  | 3,000 |
2029 |  | 3,550 |
Thereafter |  | 59,802 |
UnitedHealth Group’s parent company had short-term notes payable to subsidiaries of $2.0 billion and $9.9 billion as of December 31, 2024 and 2023, respectively, which included on-demand features. UnitedHealth Group’s parent company had long-term notes payable to subsidiaries of $14.4 billion as of December 31, 2024. 4. Commitments and Contingencies Certain subsidiaries are guaranteed by UnitedHealth Group’s parent company in the event of insolvency. UnitedHealth Group’s parent company also provides guarantees related to its service level under certain contracts. None of the amounts accrued, paid or charged to income for service level guarantees were material as of December 31, 2024, 2023 or 2022. For a summary of commitments and contingencies, see Note 12 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11 + Details
Name: | srt_CondensedStatementOfIncomeCaptionsLineItems
Namespace Prefix: | srt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11 + Details
Name: | us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration